Editas Medicine Inc (EDIT) concluded trading on Thursday at a closing price of $2.18, with 3.15 million shares of worth about $6.86 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -2.24% during that period and on June 12, 2025 the price saw a gain of about 7.39%. Currently the company’s common shares owned by public are about 83.71M shares, out of which, 82.95M shares are available for trading.
Stock saw a price change of 21.11% in past 5 days and over the past one month there was a price change of 45.33%. Year-to-date (YTD), EDIT shares are showing a performance of 71.65% which decreased to -59.02% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.91 but also hit the highest price of $6.22 during that period. The average intraday trading volume for Editas Medicine Inc shares is 1.93 million. The stock is currently trading 24.09% above its 20-day simple moving average (SMA20), while that difference is up 42.81% for SMA50 and it goes to 3.64% higher than SMA200.
Editas Medicine Inc (NASDAQ: EDIT) currently have 83.71M outstanding shares and institutions hold larger chunk of about 54.29% of that.
The stock has a current market capitalization of $182.50M and its 3Y-monthly beta is at 2.10. It has posted earnings per share of -$3.04 in the same period. It has Quick Ratio of 3.08 while making debt-to-equity ratio of 0.50. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EDIT, volatility over the week remained 5.51% while standing at 5.79% over the month.
Analysts are in expectations that Editas Medicine Inc (EDIT) stock would likely to be making an EPS of -0.37 in the current quarter, while forecast for next quarter EPS is -0.33 and it is -1.1 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.44 which is -0.29 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.82 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 36.08% while it is estimated to increase by 38.84% in next year. EPS is likely to grow at an annualized rate of 26.11% for next 5-years, compared to annual growth of -1.48% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on April 28, 2025 offering a Buy rating for the stock and assigned a target price of $3 to it. On December 13, 2024, Truist Downgrade their recommendations, while on December 13, 2024, Stifel Downgrade their ratings for the stock with a price target of $3. Stock get a Neutral rating from Chardan Capital Markets on December 13, 2024.
